Cargando…

A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers

OBJECTIVES: To evaluate the trends in patterns of disease-modifying antirheumatic drugs (DMARDs) and biological agents use from 1999 to 2009 and to identify patient characteristics associated with different patterns of their use in a national sample of Veterans with rheumatoid arthritis (RA). DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Bernard, Chu, Adeline, Khan, Myrna M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641511/
https://www.ncbi.nlm.nih.gov/pubmed/23562815
http://dx.doi.org/10.1136/bmjopen-2012-002468
_version_ 1782268039308247040
author Ng, Bernard
Chu, Adeline
Khan, Myrna M
author_facet Ng, Bernard
Chu, Adeline
Khan, Myrna M
author_sort Ng, Bernard
collection PubMed
description OBJECTIVES: To evaluate the trends in patterns of disease-modifying antirheumatic drugs (DMARDs) and biological agents use from 1999 to 2009 and to identify patient characteristics associated with different patterns of their use in a national sample of Veterans with rheumatoid arthritis (RA). DESIGN: A retrospective cohort study. SETTINGS: Administrative databases of the USA Department of Veterans Affairs. PARTICIPANTS: An incident cohort of 13 254 patients with newly diagnosed RA was identified. PRIMARY OUTCOME MEASURES: Trends and choice of DMARDs and biological agents’ usage, and time intervals between RA diagnosis and treatment RESULTS: Methotrexate use as first-line agent increased from 39.9% to 57.2% over the study period (p<0.001). Although biological dispensations increased over other DMARDs and biological agents, from 3.4% to 25% from 1999 to 2009, the percentage of RA patients diagnosed between 1999 and 2007 who had biologics dispensations remained steady at 23.3–26.7%. Compared with Caucasian, African Americans were less likely to receive biologics (HR 0.71, 95% CI 0.63 to 0.81). Patients aged 75 and older were less likely to receive biologics than those younger than 45 (HR 0.29, 95% CI 0.23 to 0.36). The time interval between RA diagnosis and treatment with DMARDs and biological agents decreased significantly over time (median: 51 days in 1999–2001 to 28 days in 2006–2007). CONCLUSIONS: Methotrexate use increased as it became the preferred first-line agent, while other traditional agents declined. Dispensation of biologics increased significantly, but the proportion of RA patients eventually given biologics stabilised below 30%. A significant shorter time between RA diagnosis and DMARD or biological agent initiation in recent years suggests improvements in quality of care. There were disproportionately lower use of biologics in certain age and ethnic groups, and further studies will be needed to elucidate these observations.
format Online
Article
Text
id pubmed-3641511
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36415112013-05-07 A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers Ng, Bernard Chu, Adeline Khan, Myrna M BMJ Open Rheumatology OBJECTIVES: To evaluate the trends in patterns of disease-modifying antirheumatic drugs (DMARDs) and biological agents use from 1999 to 2009 and to identify patient characteristics associated with different patterns of their use in a national sample of Veterans with rheumatoid arthritis (RA). DESIGN: A retrospective cohort study. SETTINGS: Administrative databases of the USA Department of Veterans Affairs. PARTICIPANTS: An incident cohort of 13 254 patients with newly diagnosed RA was identified. PRIMARY OUTCOME MEASURES: Trends and choice of DMARDs and biological agents’ usage, and time intervals between RA diagnosis and treatment RESULTS: Methotrexate use as first-line agent increased from 39.9% to 57.2% over the study period (p<0.001). Although biological dispensations increased over other DMARDs and biological agents, from 3.4% to 25% from 1999 to 2009, the percentage of RA patients diagnosed between 1999 and 2007 who had biologics dispensations remained steady at 23.3–26.7%. Compared with Caucasian, African Americans were less likely to receive biologics (HR 0.71, 95% CI 0.63 to 0.81). Patients aged 75 and older were less likely to receive biologics than those younger than 45 (HR 0.29, 95% CI 0.23 to 0.36). The time interval between RA diagnosis and treatment with DMARDs and biological agents decreased significantly over time (median: 51 days in 1999–2001 to 28 days in 2006–2007). CONCLUSIONS: Methotrexate use increased as it became the preferred first-line agent, while other traditional agents declined. Dispensation of biologics increased significantly, but the proportion of RA patients eventually given biologics stabilised below 30%. A significant shorter time between RA diagnosis and DMARD or biological agent initiation in recent years suggests improvements in quality of care. There were disproportionately lower use of biologics in certain age and ethnic groups, and further studies will be needed to elucidate these observations. BMJ Publishing Group 2013-04-05 /pmc/articles/PMC3641511/ /pubmed/23562815 http://dx.doi.org/10.1136/bmjopen-2012-002468 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
spellingShingle Rheumatology
Ng, Bernard
Chu, Adeline
Khan, Myrna M
A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
title A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
title_full A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
title_fullStr A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
title_full_unstemmed A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
title_short A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
title_sort retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at veteran affairs medical centers
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641511/
https://www.ncbi.nlm.nih.gov/pubmed/23562815
http://dx.doi.org/10.1136/bmjopen-2012-002468
work_keys_str_mv AT ngbernard aretrospectivecohortstudy10yeartrendofdiseasemodifyingantirheumaticdrugsandbiologicalagentsuseinpatientswithrheumatoidarthritisatveteranaffairsmedicalcenters
AT chuadeline aretrospectivecohortstudy10yeartrendofdiseasemodifyingantirheumaticdrugsandbiologicalagentsuseinpatientswithrheumatoidarthritisatveteranaffairsmedicalcenters
AT khanmyrnam aretrospectivecohortstudy10yeartrendofdiseasemodifyingantirheumaticdrugsandbiologicalagentsuseinpatientswithrheumatoidarthritisatveteranaffairsmedicalcenters
AT ngbernard retrospectivecohortstudy10yeartrendofdiseasemodifyingantirheumaticdrugsandbiologicalagentsuseinpatientswithrheumatoidarthritisatveteranaffairsmedicalcenters
AT chuadeline retrospectivecohortstudy10yeartrendofdiseasemodifyingantirheumaticdrugsandbiologicalagentsuseinpatientswithrheumatoidarthritisatveteranaffairsmedicalcenters
AT khanmyrnam retrospectivecohortstudy10yeartrendofdiseasemodifyingantirheumaticdrugsandbiologicalagentsuseinpatientswithrheumatoidarthritisatveteranaffairsmedicalcenters